Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
1.
Langmuir ; 33(31): 7715-7721, 2017 08 08.
Artigo em Inglês | MEDLINE | ID: mdl-28689408

RESUMO

Oligomeric peptides exist widely in living organisms and play a role in a broad range of biological functions. We report the first observation of liquid-liquid phase separation (LLPS) in peptide solutions, in particular, solutions of peptides consisting of noncovalent oligomers. We determined the binary phase boundary of the oligomeric peptide solution and compared the result to the well-established phase diagram of globular proteins. We also provide simple theoretical interpretations of the similarities and differences between the phase diagrams of peptides and proteins. Finally, by tuning inter-oligomer interactions using a crowding agent, we demonstrated that LLPS is a universal phenomenon that can be observed under different solution conditions for a variety of peptides.


Assuntos
Peptídeos/química , Anticorpos , Proteínas , Soluções
2.
Mol Pharm ; 12(2): 411-9, 2015 Feb 02.
Artigo em Inglês | MEDLINE | ID: mdl-25569709

RESUMO

Oligomerization of lipidated peptides is of general scientific interest and is important in biomedical and pharmaceutical applications. We investigated the solution properties of a lipidated peptide, Liraglutide, which is one of the glucagon-like peptide-1 (GLP-1) agonists used for the treatment of type II diabetes. Liraglutide can serve as a model system for studying biophysical and biochemical properties of micelle-like self-assemblies of the lipidated peptides. Here, we report a transformation induced in Liraglutide oligomers by changing pH in the vicinity of pH 7. This fully reversible transformation is characterized by changes in the size and aggregation number of the oligomer and an associated change in the secondary structure of the constituent peptides. This transformation has quite slow kinetics: the equilibrium is reached in a course of several days. Interestingly, while the transformation is induced by changing pH, its kinetics is essentially independent of the final pH. We interpreted these findings using a model in which desorption of the monomer from the oligomer is the rate-limiting step in the transformation, and we determined the rate constant of the monomer desorption.


Assuntos
Peptídeos/química , Polímeros/química , Peptídeo 1 Semelhante ao Glucagon/agonistas , Concentração de Íons de Hidrogênio , Incretinas/química , Cinética , Liraglutida/química
3.
Eur J Pharm Biopharm ; 158: 198-210, 2021 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-33248268

RESUMO

The natural capacity of extracellular vesicles (EVs) to transport their payload to recipient cells has raised big interest to repurpose EVs as delivery vehicles for xenobiotics. In the present study, bovine milk-derived EVs (BMEVs) were investigated for their potential to shuttle locked nucleic acid-modified antisense oligonucleotides (LNA ASOs) into the systemic circulation after oral administration. To this end, a broad array of analytical methods including proteomics and lipidomics were used to thoroughly characterize BMEVs. We found that additional purification by density gradients efficiently reduced levels of non-EV associated proteins. The potential of BMEVs to functionally transfer LNA ASOs was tested using advanced in vitro systems (i.e. hPSC-derived neurons and primary human cells). A slight increase in cellular LNA ASO internalization and target gene reduction was observed when LNA ASOs were delivered using BMEVs. When dosed orally in mice, only a small fraction (about 1% of total administered dose) of LNA ASOs was recovered in the peripheral tissues liver and kidney, however, no significant reduction in target gene expression (i.e. functional knockdown) was observed.


Assuntos
Portadores de Fármacos/química , Vesículas Extracelulares/química , Leite/citologia , Oligonucleotídeos Antissenso/administração & dosagem , Oligonucleotídeos/administração & dosagem , Administração Oral , Animais , Composição de Medicamentos/métodos , Avaliação Pré-Clínica de Medicamentos , Humanos , Camundongos , Neurônios , Oligonucleotídeos/farmacocinética , Oligonucleotídeos Antissenso/farmacocinética , Células-Tronco Pluripotentes , Cultura Primária de Células , Distribuição Tecidual
4.
Eur J Pharm Sci ; 115: 126-131, 2018 Mar 30.
Artigo em Inglês | MEDLINE | ID: mdl-29278757

RESUMO

Wet media milling is a well-established unit operation for the manufacturing of suspension formulations during early phase pharmaceutical development. However, knowledge about the kinetics of particle breakage is limited, although the impact of hydro-mechanical process parameters on the mean particle size of finished suspensions has been thoroughly investigated. We performed in this work milling trials with two different compounds on two milling devices with different mechanical design and volume scale. We analyzed our data in terms of a kinetic milling model where we included the milling speed as an explicit process parameter in addition to the process duration. We show, that the milling kinetics can be fairly well predicted for a wide range of these operating parameters. The proposed milling model may therefore be useful for rational process planning and scale-up considerations in the industrial setting.


Assuntos
Preparações Farmacêuticas/química , Química Farmacêutica/métodos , Composição de Medicamentos/métodos , Cinética , Tamanho da Partícula , Suspensões/química
5.
J Control Release ; 241: 25-33, 2016 11 10.
Artigo em Inglês | MEDLINE | ID: mdl-27578099

RESUMO

Hybrid incretin peptides are a new generation of drugs for the treatment of diabetes and obesity. Despite their biological potency, the effectiveness of these peptides as drugs is limited by their short circulation time in blood (typically within minutes). In this work, we show that lipid conjugated forms of a GLP-1/GIP/glucagon hybrid peptides stay in circulation for hours. We studied the oligomerization and albumin-binding of the unconjugated hybrid peptide as well as its lipidated variants. These lipidated peptides differ in the N-terminal mutation, the position of lipidation and the linkage to lipid. We found that these lipidated peptides form stable oligomers at concentrations above 1mg/mL. This concentration range is relevant to formulation and storage of the peptides. We observed no binding between the peptide oligomers and human serum albumin. However, at the expected therapeutic concentration range (~10-100ng/mL), the oligomers dissociate into monomers. The monomers of lipidated peptides bind to albumin. We have determined the dissociation constants of binding between the lipidated peptides and serum albumin. The dissociation constants of albumin-binding of our lipidated peptides are all very close and similar to that of the fatty acid binding of albumin. Our findings suggest that the monomeric lipidated peptides bind to HSA mainly by the fatty acid chain. Therefore, albumin binding is likely to be a universal mechanism of the prolonged circulating duration of lipidated pharmaceutical peptides.


Assuntos
Peptídeo 1 Semelhante ao Glucagon/análogos & derivados , Peptídeo 1 Semelhante ao Glucagon/sangue , Incretinas/sangue , Albumina Sérica/metabolismo , Animais , Peptídeo 1 Semelhante ao Glucagon/metabolismo , Meia-Vida , Humanos , Incretinas/metabolismo , Injeções Subcutâneas , Masculino , Ligação Proteica , Ratos Wistar , Fatores de Tempo
7.
Eur J Pharm Biopharm ; 85(3 Pt B): 833-42, 2013 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-23665448

RESUMO

Biopharmaceutics is routinely used in the design and development of medicines to generate science based evidence to predict in vivo performance; the application of this knowledge specifically to paediatric medicines development is yet to be explored. The aim of this review is to present the current status of available biopharmaceutical tools and tests including solubility, permeability and dissolution that may be appropriate for use in the development of immediate release oral paediatric medicines. The existing tools used in adults are discussed together with any limitations for their use within paediatric populations. The results of this review highlight several knowledge gaps in current methodologies in paediatric biopharmaceutics. The authors provide recommendations based on existing knowledge to adapt tests to better represent paediatric patient populations and also provide suggestions for future research that may lead to better tools to evaluate paediatric medicines.


Assuntos
Biofarmácia/métodos , Tecnologia Farmacêutica/métodos , Absorção , Administração Oral , Adulto , Biofarmácia/tendências , Química Farmacêutica/métodos , Química Farmacêutica/tendências , Criança , Simulação por Computador , Sistemas de Liberação de Medicamentos , Interações Alimento-Droga , Humanos , Concentração de Íons de Hidrogênio , Absorção Intestinal/efeitos dos fármacos , Pediatria , Permeabilidade , Preparações Farmacêuticas/administração & dosagem , Preparações Farmacêuticas/síntese química , Solubilidade , Tecnologia Farmacêutica/tendências
8.
Int J Pharm ; 435(2): 124-30, 2012 Oct 05.
Artigo em Inglês | MEDLINE | ID: mdl-22677416

RESUMO

There is some confusion about the types of paediatric pharmaceutical preparation (in a regulatory and pharmaceutical development context) that are acceptable for approval by medicines regulators. Some of the confusion relates to terminology which may mean different things to different stakeholders. It may not always be possible to provide authorised, commercially manufactured, age appropriate, ready-to-administer preparations. In terms of assurance of quality and bioavailability there is a continuum from this ideal through intermediate products through authorised compounding and manipulation of commercial dosage forms to ad hoc compounding using only the skills and experience of the individual pharmacist. Additionally, it is widely known that caregivers may manipulate medicines at home, for example by segmenting tablets and by addition to foods or liquids. The first intent of the manufacturer should be to provide for children an age appropriate, ready-to-administer preparation which is commercially manufactured and approved by the competent authorities. However, there will still be a place for providing other age appropriate preparations such as approved products that are 'intermediates' requiring reconstitution before use, or instructions for compounding or manipulation of a dosage form. If compounding or manipulation is likely to be required it is preferable that data are generated by Industry, approved by the competent authorities and provided in the Summary of Product Characteristics (SmPC). It is acknowledged however, that ad hoc compounding or manipulation may also take place in certain circumstances such as logistical difficulties or to satisfy the needs of the child who does not find the authorised product to be 'age appropriate'. This paper explores compounding and manipulation of medicines in relation to approval by medicines regulators and non-approved preparation to fulfil the needs of the individual patient. Definitions are proposed to provide a hierarchical classification based on assurances of quality and bioavailability.


Assuntos
Preparações Farmacêuticas , Criança , Aprovação de Drogas , Composição de Medicamentos , Humanos , Preparações Farmacêuticas/administração & dosagem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA